Rapid Dose Therapeutics Launches QuickStrip Medical Cannabis in Brazil Following ANVISA Approval
Key Insights
Rapid Dose Therapeutics (search) has officially launched its QuickStrip (search) medical cannabis product in Brazil after receiving regulatory approval from ANVISA for both manufacturing and distribution.
The approval allows for sublingual and buccal administration, positioning the company among the first to bring an orally dissolvable strip cannabis therapy to the Brazilian medical market.
Brazil represents a significant growth opportunity with over 215 million people and 672,000 registered cannabis patients, a figure that increased 56 percent year over year.
Rapid Dose Therapeutics (search) Corp. has officially launched its QuickStrip (search) medical cannabis product in Brazil following regulatory approval from the country's National Health Regulatory Agency, ANVISA. The approval covers both manufacturing and distribution and allows for sublingual and buccal administration, positioning the Canadian biotechnology company among the first to bring an orally dissolvable strip cannabis therapy to the Brazilian medical market.
The Brazilian launch is being executed through a strategic partnership with Nexxions (search), the company's U.S.-based distribution and commercialization partner, and Entourage Phytolab (search), a Brazilian pharmaceutical company specializing in cannabinoid-based medicines. Nexxions played a key role in navigating Brazil's regulatory framework and securing market access in what remains a highly regulated environment.
Expanding Market Opportunity
Brazil represents one of the most attractive growth opportunities for medical cannabis globally. With a population exceeding 215 million, the country has reported more than 672,000 registered cannabis patients, a figure that rose 56 percent year over year. Recent regulatory changes in January 2026 expanded permitted routes of administration to include sublingual and buccal delivery, alongside dermatological and inhalation methods, significantly broadening treatment options for patients.
The regulatory shift comes as medical cannabis enters a new phase of global adoption, with regulators expanding approved delivery methods beyond oils and inhalation. Across large emerging healthcare markets, physicians and patients are increasingly focused on formats that offer faster onset, precise dosing, and improved adherence, particularly for chronic conditions where consistency and discretion matter.
QuickStrip Technology Advantages
QuickStrip (search) is designed to address several limitations associated with oils, capsules, and inhaled products. The rapidly dissolving oral thin film delivers controlled doses of active ingredients through the oral mucosa, enabling faster absorption and more predictable effects compared to traditional oral formulations. Oral mucosal absorption offers rapid onset, while the thin strip format allows for discreet, portable use.
Precise dosing supports physician oversight and treatment consistency, and the non-inhalable format makes the product suitable for patients with respiratory concerns. Executives at Entourage Phytolab (search) cited early patient feedback showing rapid relief, often within minutes, and longer-than-expected duration of benefit. Company leadership highlighted the ease of use as a key differentiator in a market where many patients struggle with swallowing pills or tolerating the taste and variability of oils.
Strategic Growth Initiative
Rapid Dose Therapeutics (search)' management described the Brazilian launch as a meaningful milestone in its broader international growth strategy, noting that partnerships in Brazil and across South America position the company to address rising demand for pharmaceutical-grade cannabis therapies as regulations continue to evolve.
The company has also expanded its presence in U.S. capital markets, with its common shares now trading on the OTCQB Venture Market under the ticker symbol RDTCF. "Trading on the OTCQB strengthens our visibility with U.S. investors and aligns with our long-term strategy to support growth, partnerships, and commercialization across multiple verticals," said Mark Upsdell, CEO of Rapid Dose Therapeutics (search).
Shares of DOSE were up 10.3 percent at C$0.16 in Tuesday afternoon trading, while RDTCF shares were flat at $0.076, reflecting investor interest in the company's international expansion efforts and innovative drug delivery platform.